Literature DB >> 22753833

Cost of tuberculosis in the era of multidrug resistance: will it become unaffordable?

Robert Loddenkemper, Giovanni Sotgiu, Carole D Mitnick.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22753833     DOI： 10.1183/09031936.00027612

Source DB:  PubMed          Journal:  Eur Respir J        ISSN： 0903-1936            Impact factor:   16.671


× No keyword cloud information.
  8 in total

Review 1.  Bedaquiline for the treatment of multidrug-resistant tuberculosis: great promise or disappointment?

Authors:  Stephen K Field
Journal:  Ther Adv Chronic Dis       Date:  2015-07       Impact factor: 5.091

2.  Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis.

Authors:  Vija Skripconoka; Manfred Danilovits; Lea Pehme; Tarmo Tomson; Girts Skenders; Tiina Kummik; Andra Cirule; Vaira Leimane; Anu Kurve; Klavdia Levina; Lawrence J Geiter; Davide Manissero; Charles D Wells
Journal:  Eur Respir J       Date:  2012-09-27       Impact factor: 16.671

3.  Minimum inhibitory concentration, pharmacokinetics/pharmacodynamics and therapeutic drug monitoring: An integrated approach for multidrug-resistant tuberculosis.

Authors:  Shashikant Srivastava
Journal:  Lung India       Date:  2015 Jul-Aug

4.  Transregional movement of multidrug-resistant tuberculosis in north China: an underlying threat to tuberculosis control.

Authors:  Jun An; Mengqiu Gao; Naihui Chu; Hairong Huang; Yu Pang; Liang Li
Journal:  Sci Rep       Date:  2016-07-14       Impact factor: 4.379

5.  Treatment outcome of multidrug-resistant tuberculosis in Japan - the first cross-sectional study of Japan tuberculosis surveillance data.

Authors:  Lisa Kawatsu; Kazuhiro Uchimura; Kiyohiko Izumi; Akihiro Ohkado; Takashi Yoshiyama
Journal:  BMC Infect Dis       Date:  2018-08-31       Impact factor: 3.090

6.  Budgetary impact of using BPaL for treating extensively drug-resistant tuberculosis.

Authors:  Christiaan Mulder; Stephan Rupert; Ery Setiawan; Elmira Mambetova; Patience Edo; Jhon Sugiharto; Sani Useni; Shelly Malhotra; Sarah Cook-Scalise; Imran Pambudi; Abdullaat Kadyrov; Adebola Lawanson; Susan van den Hof; Agnes Gebhard; Sandeep Juneja; Hojoon Sohn
Journal:  BMJ Glob Health       Date:  2022-01

7.  Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement.

Authors:  Christoph Lange; Ibrahim Abubakar; Jan-Willem C Alffenaar; Graham Bothamley; Jose A Caminero; Anna Cristina C Carvalho; Kwok-Chiu Chang; Luigi Codecasa; Ana Correia; Valeriu Crudu; Peter Davies; Martin Dedicoat; Francis Drobniewski; Raquel Duarte; Cordula Ehlers; Connie Erkens; Delia Goletti; Gunar Günther; Elmira Ibraim; Beate Kampmann; Liga Kuksa; Wiel de Lange; Frank van Leth; Jan van Lunzen; Alberto Matteelli; Dick Menzies; Ignacio Monedero; Elvira Richter; Sabine Rüsch-Gerdes; Andreas Sandgren; Anna Scardigli; Alena Skrahina; Enrico Tortoli; Grigory Volchenkov; Dirk Wagner; Marieke J van der Werf; Bhanu Williams; Wing-Wai Yew; Jean-Pierre Zellweger; Daniela Maria Cirillo
Journal:  Eur Respir J       Date:  2014-03-23       Impact factor: 16.671

Review 8.  Implications of human activities for (re)emerging infectious diseases, including COVID-19.

Authors:  Nundu Sabiti Sabin; Akintije Simba Calliope; Shirley Victoria Simpson; Hiroaki Arima; Hiromu Ito; Takayuki Nishimura; Taro Yamamoto
Journal:  J Physiol Anthropol       Date:  2020-09-25       Impact factor: 2.867
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.